Dr. Neil Cashman, Chief Scientific Officer at ProMIS Neurosciences, and a Professor and Canada Research Chair at the University of British Columbia, presented at the “third annual R&D Technologies Conference: Exploring Cutting-edge Technologies in Pre-clinical Neuroscience Studies” on September 28th. The conference was held in London, UK, and was centered on current market trends, technological advancements, and future challenges in the field of pre-clinical neuroscience research. It brings a call to action for all the leading experts from the research institutes and the pharmaceutical industry, to assess the most recent advancements in neuroscience technologies. This is done through a number of different methods, which includes keynotes, case studies and discussion panels. ProMIS’ focus is on the discovery and creation of biotechnology for the treatment of neurodegenerative diseases. They will be presenting the use of their discovery platform to determine therapeutic targets on misfolded proteins that lead to many neurodegenerative diseases. Dr. Cashman outlines the effects that these toxic folds and their role in Alzheimer's disease and amyotrophic lateral sclerosis (ALS) in his presentation entitled “Misfolding Proteins in Neurodegenerative Diseases”.
SOURCE: Newswire, September 28th, 2017,
AUTHOR: ProMIS Neurosciences Inc.
DATE RETRIEVED: September 29th, 2017